智通财经APP获悉，荣昌生物(09995)一度涨超9%，截至发稿，涨6.25%，报55.3港元，成交额6.98亿港元。
消息面上，近日，荣昌生物公布，公司的产品泰它西普(商品名：泰爱®，研发代号：RC18)获得欧盟委员会(EC)授予的孤儿药资格认定(Orphan Drug Designation,ODD)，用于治疗重症肌无力。值得关注的是，此前6月11日晚，荣昌生物官微发文称，第62届欧洲肾脏病学会年会现场，有多位跨国医药公司BD经理主动接洽，围绕泰它西普的国际合作、技术授权等商业拓展方向展开深度交流。
瑞银此前研报指出，荣昌生物年初至今股价已累升三倍，高于行业的64%升幅，主要因其管线产品的进展，而配股7.96亿港元亦缓解集团紧张的财务状况。该行认为从12个月的角度来看，集团股价合理，近期主要的正面催化剂已于股价中反映，将评级由原先“买入”下调至“中性”。另外，将RC18的全球销售及估算开支纳入考虑，目标价由33.7港元大幅上调至63.8港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.